Exscientia Ltd ADR

NASDAQ EXAI

Data sourced from

and

Download Data

Exscientia Ltd ADR Capital Expenditure To Sales 3 year CAGR for the year ending December 31, 2023: 75.71%

Exscientia Ltd ADR Capital Expenditure To Sales 3 year CAGR is 75.71% for the year ending December 31, 2023, a 17.99% change year over year. The capital expenditure ratio measures the proportion of a company's revenue allocated to capital expenditures. It is calculated by dividing capital expenditures by revenue. This ratio indicates the extent to which a company invests in long-term assets relative to its sales. A higher ratio suggests a higher level of investment in the expansion and improvement of the company's asset base. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Exscientia Ltd ADR Capital Expenditure To Sales for the year ending December 31, 2022 was 82.54%, a 135.94% change year over year.
Exscientia Ltd ADR Capital Expenditure To Sales for the year ending December 31, 2021 was 34.98%, a 42.95% change year over year.
Exscientia Ltd ADR Capital Expenditure To Sales for the year ending December 31, 2020 was 24.47%, a 31.18% change year over year.
Exscientia Ltd ADR Capital Expenditure To Sales for the year ending December 31, 2019 was 18.66%.

NASDAQ: EXAI

Exscientia Ltd ADR

CEO	Prof. Andrew L. Hopkins DPHIL, FRSE FRSC
IPO Date	Oct. 1, 2021
Location	United Kingdom
Headquarters	The SchrOedinger Building, Oxford, United Kingdom, OX4 4GE
Employees	483
Sector	Healthcare
Industry	Biotechnology

Description

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité " Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

Key trends